Table 1. Comparability of study and... | American Society of Hematology

Table 1.

Comparability of study and control patients

	Study (N = 21)		Control (N = 100)
	N	%	N	%
Phase II-CCB or T^*
Stage II 4-9+ node	3	14	14	14
Stage II 10+ node	7	32	32	32
Stage III, inflammatory	2^*	10	10^*	10
Stage IV, measurable	2	10	10	10
Stage IV, NED	1^*	23	24	24
Phase I, TCM
Stage IV, measurable	2	10	10	10

	Study (N = 21)		Control (N = 100)
	N	%	N	%
Phase II-CCB or T^*
Stage II 4-9+ node	3	14	14	14
Stage II 10+ node	7	32	32	32
Stage III, inflammatory	2^*	10	10^*	10
Stage IV, measurable	2	10	10	10
Stage IV, NED	1^*	23	24	24
Phase I, TCM
Stage IV, measurable	2	10	10	10

NED, no evidence of disease; TCM, taxotere-carboplatin.

Received CCT (cyclophosphamide-cisplatin-taxol; N = 3). Remaining phase II patients received CCB (cyclophosphamide-cisplatin-BCNU).